994 results on '"Mansur, Rodrigo B."'
Search Results
2. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
3. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
4. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®)
5. Effect of intravenous ketamine on suicidality in adults with treatment-resistant depression: A real world effectiveness study
6. Association between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis
7. Electroencephalography (EEG) spectral signatures of selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs) and vortioxetine in major depressive disorder: A systematic review
8. Central effects of acute intranasal insulin on neuroimaging, cognitive, and behavioural outcomes: A systematic review
9. Metabolic factors modulate effort-based decision-making in major depressive disorder
10. Examining the impact of comorbid posttraumatic stress disorder on ketamine's real-world effectiveness in treatment-resistant depression
11. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists
12. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
13. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
14. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
15. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
16. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
17. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
18. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
19. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review
20. Peripheral inflammatory biomarkers define biotypes of bipolar depression
21. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
22. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review
23. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis
24. Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD
25. Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders
26. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity
27. Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
28. Association between depressive symptoms and bone density in elderly patients with non-dialysis dependent chronic kidney disease
29. The association between stage of treatment-resistant depression and clinical utility of ketamine/esketamine: A systematic review
30. The effect of adjunctive infliximab treatment on future cardiovascular disease risk in patients with bipolar disorder
31. Evaluating cognitive function in unaffected relatives of individuals with bipolar disorders: A meta-analysis
32. The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies
33. Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
34. Psychedelics for the Treatment of Psychiatric Disorders: Interpreting and Translating Available Evidence and Guidance for Future Research.
35. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis
36. Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: A systematic review and meta-analysis
37. What not to use in bipolar disorders: A systematic review of non-recommended treatments in clinical practice guidelines
38. Comparing mortality from covid-19 to mortality due to overdose: A micromort analysis
39. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis
40. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the united states food and drug administration adverse event reporting system (FAERS)
41. 271. Maintenance Ketamine Infusions Demonstrate Sustained Antidepressant Efficacy in a Real-World Treatment-Resistant Unipolar and Bipolar Depression Sample
42. Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
43. Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects
44. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine
45. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic review
46. Repetitive transcranial magnetic stimulation for cognitive function in adults with bipolar disorder: A pilot study
47. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
48. The effect of intravenous ketamine on cognitive functions in adults with treatment-resistant major depressive or bipolar disorders: Results from the Canadian rapid treatment center of excellence (CRTCE)
49. Government response moderates the mental health impact of COVID-19: A systematic review and meta-analysis of depression outcomes across countries
50. The Prevalence of Suicidal Behaviour in Fibromyalgia Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.